Prognostic Role of Serum Cytokines Level in Non-small Cell Lung Cancer Patients with Anti-PD-1 and Chemotherapy Combined Treatment

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2024 Nov 6

PMID 39502692

Authors

Hongyu Liu

Chao Zhou

Haohua Jiang

Tianqing Chu

Runbo Zhong

Xueyan Zhang

Yinchen Shen

Baohui Han

Affiliations

Soon will be listed here.

Abstract

Background: Chemotherapy combined with PD-1 inhibitor treatment has revolutionized the standard of care for patients with NSCLC. However, the benefit is not universal, highlighting the need for precise prediction factors. Given their relationship with the immune system and non-invasive nature, serum cytokines are potential candidates for predicting the clinical effects of chemoimmunotherapy. Our study aims to evaluate the association of serum cytokines with the prognosis of patients with NSCLC treated with chemoimmunotherapy.

Methods: Levels of 10 serum cytokines were detected in 60 NSCLC patients receiving chemotherapy plus PD-1 inhibitor-based treatment. Of these, dynamic samples from 19 patients were collected at baseline and after two treatment cycles. Their association with patients' clinicopathological characteristics, PFS and OS was described and investigated using survival analysis, cox regression and time-dependent ROC analysis. Preliminary evaluation of changes in cytokine levels associated with treatment response was conducted.

Results: Patients with lower baseline levels of serum IL-6, IL-5, IL-8, TNF-α and IL-10 had longer PFS, while patients with higher levels of IL-4 had longer PFS. Patients with lower levels of serum IL-6, IL-8, IL-22, TNF-α and IL-10 had longer OS, while patients with higher levels of IL-4 had longer OS. Multivariate analysis suggested that higher IL-6 and IL-5 levels were associated with poorer PFS, and higher IL-6 levels were associated with dismal OS. Additionally, changes in serum cytokine levels could be associated with treatment response.

Conclusion: Our study suggests that serum cytokines, specifically IL-6, IL-5, IL-8, TNF-α, IL-10, and IL-4, are potential prognostic factors for patients with NSCLC receiving chemotherapy plus PD-1 inhibitor treatment.

Citing Articles

Predictive value of serum cytokines in patients with non-small-cell lung cancer receiving anti-PD-1 blockade therapy: a meta-analysis.

Liu Q, Shaibu Z, Xu A, Yang F, Cao R, Yang F Clin Exp Med. 2025; 25(1):59.

PMID: 39955679 PMC: 11830645. DOI: 10.1007/s10238-025-01587-1.

References

Mascaux C, Angelova M, Vasaturo A, Beane J, Hijazi K, Anthoine G . Immune evasion before tumour invasion in early lung squamous carcinogenesis. Nature. 2019; 571(7766):570-575. DOI: 10.1038/s41586-019-1330-0. View

Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gumus M, Mazieres J . Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N Engl J Med. 2018; 379(21):2040-2051. DOI: 10.1056/NEJMoa1810865. View

Rios-Hoyo A, Arriola E . Immunotherapy and brain metastasis in lung cancer: connecting bench side science to the clinic. Front Immunol. 2023; 14:1221097. PMC: 10590916. DOI: 10.3389/fimmu.2023.1221097. View

Li Z, Chen L, Qin Z . Paradoxical roles of IL-4 in tumor immunity. Cell Mol Immunol. 2009; 6(6):415-22. PMC: 4003035. DOI: 10.1038/cmi.2009.53. View

Zou D, Song A, Yong W . Prognostic role of IL-8 in cancer patients treated with immune checkpoint inhibitors: a system review and meta-analysis. Front Oncol. 2023; 13:1176574. PMC: 10446970. DOI: 10.3389/fonc.2023.1176574. View

Waldmann T . Cytokines in Cancer Immunotherapy. Cold Spring Harb Perspect Biol. 2017; 10(12). PMC: 6280701. DOI: 10.1101/cshperspect.a028472. View

Hogdall D, ORourke C, Dehlendorff C, Larsen O, Jensen L, Johansen A . Serum IL6 as a Prognostic Biomarker and IL6R as a Therapeutic Target in Biliary Tract Cancers. Clin Cancer Res. 2020; 26(21):5655-5667. PMC: 8998158. DOI: 10.1158/1078-0432.CCR-19-2700. View

West H, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter H . Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase.... Lancet Oncol. 2019; 20(7):924-937. DOI: 10.1016/S1470-2045(19)30167-6. View

Waugh D, Wilson C . The interleukin-8 pathway in cancer. Clin Cancer Res. 2008; 14(21):6735-41. DOI: 10.1158/1078-0432.CCR-07-4843. View

10.

Zhao Q, Bi Y, Sun H, Xiao M . Serum IL-5 and IFN- Are Novel Predictive Biomarkers for Anti-PD-1 Treatment in NSCLC and GC Patients. Dis Markers. 2021; 2021:5526885. PMC: 8235970. DOI: 10.1155/2021/5526885. View

11.

Liu C, Yang L, Xu H, Zheng S, Wang Z, Wang S . Systematic analysis of IL-6 as a predictive biomarker and desensitizer of immunotherapy responses in patients with non-small cell lung cancer. BMC Med. 2022; 20(1):187. PMC: 9102328. DOI: 10.1186/s12916-022-02356-7. View

12.

Jotte R, Cappuzzo F, Vynnychenko I, Stroyakovskiy D, Rodriguez-Abreu D, Hussein M . Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial. J Thorac Oncol. 2020; 15(8):1351-1360. DOI: 10.1016/j.jtho.2020.03.028. View

13.

Santana-Davila R . Chemo and Immuno-Therapeutic Options for Nonsmall Cell Lung Cancer Lung Cancer. Surg Clin North Am. 2022; 102(3):493-498. DOI: 10.1016/j.suc.2022.02.005. View

14.

Abhimanyu , Bose M, Varma-Basil M, Jain A, Sethi T, Kumar Tiwari P . Establishment of Elevated Serum Levels of IL-10, IL-8 and TNF-β as Potential Peripheral Blood Biomarkers in Tubercular Lymphadenitis: A Prospective Observational Cohort Study. PLoS One. 2016; 11(1):e0145576. PMC: 4718686. DOI: 10.1371/journal.pone.0145576. View

15.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

16.

Berraondo P, Sanmamed M, Ochoa M, Etxeberria I, Aznar M, Perez-Gracia J . Cytokines in clinical cancer immunotherapy. Br J Cancer. 2018; 120(1):6-15. PMC: 6325155. DOI: 10.1038/s41416-018-0328-y. View

17.

Peng Y, Qi Q, Zhu M, Zhang Y, Bao Y, Liu Y . Plasma levels of 12 different cytokines correlate to PD-1 inhibitor combined chemotherapy responses in advanced non-small-cell lung cancer patient. Int Immunopharmacol. 2023; 124(Pt A):110888. DOI: 10.1016/j.intimp.2023.110888. View

18.

Doroshow D, Bhalla S, Beasley M, Sholl L, Kerr K, Gnjatic S . PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2021; 18(6):345-362. DOI: 10.1038/s41571-021-00473-5. View

19.

Walk E, Yohe S, Beckman A, Schade A, Zutter M, Pfeifer J . The Cancer Immunotherapy Biomarker Testing Landscape. Arch Pathol Lab Med. 2019; 144(6):706-724. DOI: 10.5858/arpa.2018-0584-CP. View

20.

Jardim D, Goodman A, Gagliato D, Kurzrock R . The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker. Cancer Cell. 2020; 39(2):154-173. PMC: 7878292. DOI: 10.1016/j.ccell.2020.10.001. View